Product Highlight - Saxenda
30 Jun 2020
Active ingredient: 1 ml of solution contains 6 mg of liraglutide. One pre-filled pen contains 18 mg liraglutide in 3 ml
Indications: Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial
Body Mass Index (BMI) of
- ≥30 kg/m² (obese), or
- ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
Dosage & Administration: The starting dose is 0.6 mg daily. The dose should be increased to 3.0 mg daily in increments of 0.6 mg with at least one week interval to improve gastro-intestinal tolerability. Saxenda® is administered once daily at any time, independent of meals, subcutaneously injected in the abdomen, thigh or upper arm, preferably around the same time every day.
NOVO NORDISK PHARMA (THAILAND) LTD.
98 Sathorn Square Office Tower, Unit 2101-2105, 21st Floor,
North Sathorn Road, Silom, Bangrak District, Bangkok 10500, Thailand
• Tel: (+66) 2237-9263-4
• Fax: (+66) 2237-9265
